BIOGEN INC. Other Comprehensive Income (Loss), Reclassification Adjustment on Derivatives Included in Net Income, Net of Tax (Deprecated 2012-01-31)
BIOGEN INC. (BIIB) reported Other Comprehensive Income (Loss), Reclassification Adjustment on Derivatives Included in Net Income, Net of Tax (Deprecated 2012-01-31) of -$9.77 million for the 12-month period ending 2011-12-31, per its 10-K filed 2012-02-03.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeReclassificationAdjustmentOnDerivativesIncludedInNetIncomeNetOfTax · last filed 2012-02-03
- BIOGEN INC. other comprehensive income (loss), reclassification adjustment on derivatives included in net income, net of tax (deprecated 2012-01-31) for fiscal 2011 was -$9.77M, a 750.27% decline from fiscal 2010.
- BIOGEN INC. other comprehensive income (loss), reclassification adjustment on derivatives included in net income, net of tax (deprecated 2012-01-31) for fiscal 2010 was $1.50M.
- BIOGEN INC. other comprehensive income (loss), reclassification adjustment on derivatives included in net income, net of tax (deprecated 2012-01-31) for fiscal 2009 was -$40.22M.
| Period end | Other Comprehensive Income (Loss), Reclassification Adjustment on Derivatives Included in Net Income, Net of Tax (Deprecated 2012-01-31) 12 month |
|---|---|
| 2011-12-31 | -$9.77M 10-K · filed 2012-02-03 |
| 2010-12-31 | $1.50M 10-K · filed 2012-02-03 |
| 2009-12-31 | -$40.22M 10-K · filed 2012-02-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |